Overview

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled AZD9164 following administration of multiple ascending doses in healthy male and female subjects and COPD patients.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca